Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC
W Brugger, N Triller, M Blasinska-Morawiec… - Journal of Clinical …, 2009 - ascopubs.org
8020 Background: The SATURN (BO18192) study investigated whether erlotinib
maintenance therapy improved PFS in patients (pts) with advanced NSCLC who had …
maintenance therapy improved PFS in patients (pts) with advanced NSCLC who had …
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
JY Wu, SG Wu, CH Yang, YL Chang, YC Chang… - Lung cancer, 2011 - Elsevier
INTRODUCTION: Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim …
R Rosell, R Gervais, A Vergnenegre… - Journal of clinical …, 2011 - ascopubs.org
7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
Background Lung cancer patients with an activating mutation in the EGFR (epidermal
growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated …
growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated …
Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC): A retrospective analysis.
8074 Background: Erlotinib is an EGFR tyrosine kinase inhibitor (TKI) which is FDA-
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …
Erlotinib: as maintenance monotherapy in non-small-cell lung cancer
VJ Muir, S Dhillon - BioDrugs, 2011 - Springer
Erlotinib is a low molecular weight, orally active, epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor. Inhibition of EGFR tyrosine kinase results in the disruption of …
tyrosine kinase inhibitor. Inhibition of EGFR tyrosine kinase results in the disruption of …
Erlotinib for frontline treatment of advanced non–small cell lung cancer: a phase II study
G Giaccone, M Gallegos Ruiz, T Le Chevalier… - Clinical Cancer …, 2006 - AACR
Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
RP Perng, CH Yang, YM Chen, GC Chang, MC Lin… - Lung Cancer, 2008 - Elsevier
PURPOSE: Erlotinib is the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) which has demonstrated a survival benefit in non-small-cell lung cancer …
(EGFR-TKI) which has demonstrated a survival benefit in non-small-cell lung cancer …
[HTML][HTML] First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
J Weiss - Translational Lung Cancer Research, 2012 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2012; 1
(3): 219-223 www. tlcr. org reported for gefitinib (15, 16). Thus, phase II studies laid a solid …
(3): 219-223 www. tlcr. org reported for gefitinib (15, 16). Thus, phase II studies laid a solid …
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …
MC Garassino, O Martelli, M Broggini, G Farina… - The lancet …, 2013 - thelancet.com
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …